Delcath Systems
Founded Year
1988Stage
PIPE - III | IPOTotal Raised
$1.39MMarket Cap
0.04BStock Price
3.71About Delcath Systems
Delcath has developed a system to isolate the liver from the general circulatory system and to administer chemotherapy and other therapeutic agents directly to the liver. Using the Delcath system to deliver chemotherapy to the liver and cleanse the blood of the chemotherapy before its return from the liver into the patient's circulatory system protects other parts of the body from the harmful side-effects of chemotherapy. The Company believes that the use of the Delcath system in treatment of liver cancer will allow higher dosages of chemotherapy to be administered to the liver than can be administered with conventional intravenous delivery.
Missing: Delcath Systems's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Delcath Systems's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Delcath Systems Patents
Delcath Systems has filed 14 patents.
The 3 most popular patent topics include:
- Experimental cancer drugs
- Cancer treatments
- Oncology
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
1/10/2020 | 2/8/2022 | Oncology, Experimental cancer drugs, Surgical oncology, Hepatology, Cancer treatments | Grant |
Application Date | 1/10/2020 |
|---|---|
Grant Date | 2/8/2022 |
Title | |
Related Topics | Oncology, Experimental cancer drugs, Surgical oncology, Hepatology, Cancer treatments |
Status | Grant |
Latest Delcath Systems News
Jan 30, 2023
01/17 01/30/2023 | 08:31am EST Message : *Required fields NEW YORK, Jan. 30, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, will participate at the BTIG MedTech, Digital Health, Life Sciences, & Diagnostics Tools Conference in Snowbird, Utah on February 14 to 16. Delcath CEO, Gerard Michel will be conducting one-on-one meetings. To request a one-on-one meeting please contact your BTIG representative with interest. About Delcath Systems, Inc. Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company's proprietary percutaneous hepatic perfusion (PHP) system is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. In the United States, the PHP system is being developed under the tradename HEPZATO™ KIT (melphalan hydrochloride for injection/Hepatic Delivery System), or HEPZATO, for the treatment of patients with unresectable hepatic-dominant metastatic ocular melanoma (mOM), also known as metastatic uveal melanoma (mUM) and is considered a combination drug and device product regulated as a drug by the United States Food and Drug Administration (FDA). In Europe, the PHP system is now regulated as a Class lll medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used at major medical centers to treat a wide range of cancers of the liver. Investor Relations Contact:
Delcath Systems Frequently Asked Questions (FAQ)
When was Delcath Systems founded?
Delcath Systems was founded in 1988.
Where is Delcath Systems's headquarters?
Delcath Systems's headquarters is located at 600 Fifth Avenue, New York.
What is Delcath Systems's latest funding round?
Delcath Systems's latest funding round is PIPE - III.
How much did Delcath Systems raise?
Delcath Systems raised a total of $1.39M.
Who are the investors of Delcath Systems?
Investors of Delcath Systems include Iroquois Capital Group, Omicron Capital, Downsview Capital, Bristol Capital Advisors, OTAPE Investments and 9 more.
Who are Delcath Systems's competitors?
Competitors of Delcath Systems include ADVOS, Saladax Biomedical, Mercator MedSystems, Affinergy, Beta-O2 Technologies and 12 more.
Compare Delcath Systems to Competitors
Mercator MedSystems has developed a broad-based therapeutic platform that allows clinicians to accurately and efficiently deliver drugs and biologics such as stem cells to tissues deep in the body, treating the root cause of significant medical conditions. The company utilizes its family of Micro-Infusion Catheters for targeted treatments via the vascular system, including peripheral artery disease (PAD) and resistant hypertension (HTN); and via the bronchial tree, including malignant airway obstruction secondary to lung cancer. The company's 510(k)-cleared and CE-Marked Cricket and Bullfrog Micro-Infusion Catheters are vascular-access systems that are able to inject drugs, genes, and cells safely through vessel walls into deep tissues without major surgery.
InfraReDx is a medical device company dedicated to helping provide practitioners with the information needed for enhanced clinical decision making in treating coronary artery disease. The company is committed to improving the safety and efficacy of coronary stenting and ultimately serving as part of a strategy to prevent initial coronary events. Through its TVC Imaging System, InfraReDx is changing the way coronary artery disease is diagnosed and treated. The TVC Imaging System is the only intravascular imaging system that enables true vessel characterization through simultaneous structural and compositional imaging data obtained in a single pullback.
Brain Tunnelgenix Technologies develops medical devices and equipment. It provides non-invasive and continuous wearable technology that tracks human brain temperature through the brain's thermal tunnel. The company was founded in 2006 and is based in Aventura, Florida.
Cardiophotonics develops non invasive blood monitors used to detect cardiac arrhythmia and dehydration
Pathfinder Therapeutics (PTI) is the developer of Explorer, an image-guided "GPS" device that enables physicians to accurately and efficiently guide the delivery of cancer therapeutics (usually resection and/or ablation) in soft-tissue organs. Explorer is cleared by the FDA in the category of Intraoperative Soft Tissue Tracking. Scout, the company's advanced 3D planning software, provides highly detailed visual and volumetric information for preoperative assessment, thus enabling clinicians to visualize the site of disease, plan the resection and/or ablation and monitor the resultant effects.
Celsense is a biotechnology company offering MRI agents that allow scientists and clinicians to monitor the location and quantity of transplanted cells. The company's products have application in the fields of regenerative medicine, immunotherapy, and the study of inflammation and immune system response. Celsense is currently collaborating with pharmaceutical and biotechnology organizations and is developing products suitable for human use.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.